Friday, August 28, 2026
CRISPR Therapeutics reports CTX310 durability data at ESC
CRISPR Therapeutics presented a late-breaking Phase 1a durability update for CTX310, its in vivo gene-editing therapy targeting ANGPTL3, at the European Society of Cardiology Congress in Munich on August 28. Across 15 participants with average follow-up of at least 60 days, the company reported no treatment-related serious adverse events and no grade 3-or-higher liver-transaminase changes, with a separate Phase 1b clinical update still due in the second half of 2026.
/ Sources
/ About this story
Compiled by Venture Atlas from the sources above, using automated AI-assisted research. This is a summary of reporting published elsewhere, not original reporting - follow the source links for the full account. See our editorial standards.
Something wrong here? Email flightatlas.contact@gmail.com and we will fix it.